Journal article
PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells
Abstract
Glioblastoma (GBM), an aggressive primary adult brain tumor, is feared for its near uniformly fatal prognosis. Despite the use of aggressive treatment including surgical resection, radiotherapy and chemotherapy, the outcome of patients with GBM has failed to improve significantly. Numerous studies have implicated CD133+GBM subpopulation as driver of chemo- and radio-resistance. CD133 expression correlates with disease progression, recurrence, …
Authors
Vora P; Venugopal C; Choksi C; Qazi M; Adams J; London M; Subapanditha M; Singh M; Bakshinyan D; Sidhu S
Journal
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, Vol. 43, No. S4, pp. s13–s14
Publisher
Cambridge University Press (CUP)
Publication Date
October 2016
DOI
10.1017/cjn.2016.367
ISSN
0317-1671